文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

阿奇霉素治疗性病性淋巴肉芽肿性直肠炎有效

Effective Treatment of Lymphogranuloma venereum Proctitis With Azithromycin.
PubMed 文献 · Clin Infect Dis · 2021-01-01

患者接受头孢曲松后分配至多西环素组或阿奇霉素组,结果显示阿奇霉素组治愈率98%,多西环素组95%,支持延长阿奇霉素给药作为替代方案。

要点

  • 阿奇霉素每周口服1g共3周对LGV直肠炎治愈率达98%。
  • 多西环素100mg每日两次共21天治愈率为95%,两组差异无统计学意义。
  • 不良事件两组相似,支持阿奇霉素作为替代治疗选择。

核心结论

  • 延长阿奇霉素给药方案可作为有症状LGV直肠炎的替代治疗选择,并为未来随机试验提供依据。

主要发现

  • 阿奇霉素组82例中80例(98%)达到LGV治愈,多西环素组43例中41例(95%)达到治愈,治疗差异2.2%[95%CI -3.2, 13.2]。
  • 微生物学治愈在阿奇霉素组为70/72(97%),多西环素组为15/15(100%),治疗差异-2.8%[95%CI -9.6, 17.7]。
  • 两组不良事件相似。

关键数值与推荐

  • LGV治愈(主要终点)定义为第6周症状缓解(临床治愈),若可获取则辅以第4周直肠PCR阴性(微生物学治愈)。
  • 所有患者先接受单剂头孢曲松1g肌内注射,随后分配至多西环素100mg每日两次共21天或阿奇霉素1g口服每周一次共3周。

临床怎么用

  • 对于有症状的LGV直肠炎,在头孢曲松基础上可考虑使用阿奇霉素1g每周一次共3周作为多西环素的替代方案。

局限性

  • 开放标签设计且按医生偏好方便分配,非随机对照,可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lymphogranuloma venereum (LGV) is a sexually transmitted infection caused by Chlamydia trachomatis (CT) serovars L1, L2, and L3 and is endemic among men who have sex with men (MSM) in Europe. We evaluated weekly oral azithromycin 1 g for 3 weeks as a treatment for LGV proctitis. METHODS: This is an open clinical trial with convenience allocation according to treating physician preferences. Adults with clinical proctitis received a single dose of 1 g of intramuscular ceftriaxone and were subsequently allocated to receive (i) doxycycline 100 mg twice daily for 21 days (Doxycycline group) or (ii) azithromycin 1 g orally once weekly for 3 weeks (Azithromycin group). LGV cure (primary endpoint) was defined as resolution of symptoms at week 6 (clinical cure, LGV-CC), with an additional supporting negative rectal polymerase chain reaction (PCR) at week 4 (microbiological cure, LGV-MC), if available. RESULTS: One hundred and twenty-five individuals with LGV clinical proctitis were included. All were MSM, and 96% were living with human immunodeficiency virus (HIV). Eighty-two were in the Azithromycin group, and 43 were in the Doxycycline group. LGV cure on a modified intention-to-treat analysis (primary endpoint), occurred in 80 of 82 (98%) in the Azithromycin group versus 41 of 43 (95%) in the Doxycycline group (treatment difference [95% confidence interval {CI}] 2.2% [-3.2, 13.2]). LGV-MC occurred in 70 of 72 (97%) vs 15 of 15 (100%) in the Azithromycin group and Doxycycline group, respectively (treatment difference [95% CI] -2.8% [-9.6; 17.7]). Adverse events were similar in both treatment groups. CONCLUSIONS: Our findings support extended azithromycin dosing as an alternative treatment option for symptomatic LGV proctitis and provides the rationale for future randomized trials.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Blanco JL, Fuertes I, Bosch J, et al. Effective Treatment of Lymphogranuloma venereum Proctitis With Azithromycin. Clin Infect Dis. 2021. PMID: 33462582. doi:10.1093/cid/ciab044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。